Weekly Digest – November 2024 Weekly Digest – November 2024 11 Nov 2024: Alphamab Oncology Unveils Promising Clinical Data on Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 at SITC 2024 Alphamab Oncology presented first-in-human results of JSKN033, a subcutaneous co-formulation combining […]
Weekly Digest – November 2024 Weekly Digest – November 2024 13 Nov 2024: $20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies ImmunoPrecise Antibodies Ltd. (IPA) has achieved a significant breakthrough in cancer research, positioning […]
Weekly Digest – November 2024 Weekly Digest – November 2024 13 Nov 2024: $20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies ImmunoPrecise Antibodies Ltd. (IPA) has achieved a significant breakthrough in cancer research, positioning […]
Weekly Digest – November 2024 Weekly Digest – November 2024 14 Nov 2024: GSK Builds Case for Blenrep with Multiple Myeloma OS Data That Bests J&J’s Darzalex GSK is focusing on Blenrep (belantamab mafodotin) for second-line multiple myeloma treatment, projecting […]
Weekly Digest – November 2024 Weekly Digest – November 2024 14 Nov 2024: Mabwell’s Novel Nectin-4 Targeting ADC 9MW2821 Approved for 2 Clinical Trials by CDE of NMPA Mabwell’s novel Nectin-4 targeting ADC, 9MW2821, has received IND approval for two […]
Weekly Digest – November 2024 Weekly Digest – November 2024 12 Nov 2024: Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer Daiichi Sankyo and AstraZeneca have […]
Weekly Digest – November 2024 Weekly Digest – November 2024 8 Nov 2024: ENHERTU Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product ENHERTU® (fam-trastuzumab deruxtecan-nxki), developed by Daiichi Sankyo and AstraZeneca, has won the prestigious 2024 Prix […]
Weekly Digest – November 2024 Weekly Digest – November 2024 12 Nov 2024: AstraZeneca, Daiichi withdraw lung cancer approval application for Enhertu follow-up and try again Daiichi Sankyo and AstraZeneca have withdrawn their FDA application for Dato-DXd in non-squamous non-small […]
